28
Views
6
CrossRef citations to date
0
Altmetric
Antimicrobial Chemotherapy

Accumulation of Azithromycin and Roxithromycin in Tracheal Epithelial Fetal Cell Lines Expressing Wild Type or Mutated Cystic Fibrosis Transmembrane Conductance Regulator Protein (CFTR)

Pages 385-392 | Published online: 18 Jul 2013

References

  • Quinton PM. Physiological basis of cystic fibrosis: a his-torical perspective. Physiol Rev 1999; 79 Suppl: S3-S22.
  • DereIle J. [Anti-inflammatory therapy in cystic fibrosis][Article in French] Arch Pediatr 2003; 10 Suppl 2: 370s-375s.
  • Martinez FJ, Simon RH. Clinical implications of macrolide therapy in chronic sinopulmonary diseases. Curr Pharm Des 2004; 10 (25): 3095–110.
  • Carey KW, Alwani A, Danziger LH, Rubinstein I. Tissue reparative effects of macrolide antibiotics in chronic inflamma-tory sinopulmonary diseases. Chest 2003; 123 (1): 261–5.
  • Hansen CR, Pressler T, Koch C, Hoiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 2005; 4: 35–40.
  • Siddiqui J. Immunomodulatory effects of macrolides: implications for practicing clinicians. Am J Med 2004; 117 Suppl 9A: 26S-29S.
  • Labro MT, Abdelghaffar H. Immunomodulation by macrolide antibiotics. J Chemother 2001; 13 (1): 3–8.
  • Labro MT. Cellular and molecular effects of macrolides Current Pharmaceut Design 2004; 10, (25): 3067-3080.
  • Labro MT. Cellular accumulation of macrolide antibi-otics. Intracellular bioactivity. In: Schönfeld W, Kirst H (Eds.). Macrolide Antibiotics. Birkhauser Verlag AG. 2002: 37-52.
  • Vazifeh D, Abdelghaffar H, Labro MT. Cellular accu-mulation of the new ketolide RU 64004 by human neu-trophils: comparison with that of azithromycin and rox-ithromycin. Antimicrob Agents Chemother 1997; 41: 2099-2107.
  • Vazifeh D, Preira A, Bryskier A, Labro MT. Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob Agents Chemother 1998; 42: 1944-1951.
  • Labro MT, Abdelghaffar H, Babin-Chevaye C. Interaction between the new ketolide, ABT-773 (cethromycin) and human polymorphonuclear neutrophils and the phagocyt-ic cell line PLB-985 in vitro. Antimicrob Agents Chemother 2004; 48: 1096-1104.
  • Abdelghaffar H, Soukri A, Babin-Chevaye C, Labro MT. Interaction of macrolides and ketolides with the phagocyt-ic cell line PLB-985. J Chemother 2003; 15 (4): 350–356.
  • Endicott JA, Ling V. The biochemistry of P-glycopro-tein-mediated multidrug resistance. Ann Rev Biochem 1989; 58: 137–171.
  • Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. Gen Pharmac 1996; 27: 1283–1291.
  • Wakasugi H, Yano I, Ito T, et al. Effect of clar-ithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998; 64: 123–128.
  • Arceci RJ, Stieglitz K, Bierer BE. Immunosuppressant FK506 and rapamycin function as reversal agents of the mul-tidrug-resistance phenotype. Blood 1992; 80: 1528-1536.
  • Crosta L, Candiloro V, Meli M, Tolomeo M, Rausa L, Dusonchet. Lacidipine and josamycin: two new multidrug resistance modulators. Anticancer Res 1994; 14: 2685-2690.
  • Saeki T, Ueda K, Tanigawara Y, Hon i R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077–6080.
  • Lemnanouar M, Chastre E, Paul A, et al. Oncogene-mediated propagation of tracheal epithelial cells from two cys-tic fibrosis fetuses with different mutations. Characterization of CFT-1 and CFT-2 cells in culture. Eur J Clin Invest 1993; 23 (3): 151-160.
  • Mergey M, Lemnaouar M, Veissiere D, et al. CFTR gene transfer corrects defective glycoconjugate secretion in human CF epithelial tracheal cells. Am J Physiol 1995; 269 (13): L855–L864.
  • Carlier MB, Scorneaux B, Zenebergh A, Desnottes JF, Tulkens PM. Cellular uptake, localization and activity of fluoro-quinolones in uninfected and infected macrophages. J Antimicrob Chemother 1990; 26 (Suppl. B): 27-39.
  • Rubin BK, Henke MO. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 2004; 125 (2 Suppl): 70S-78S.
  • Schultz MJ. Macrolide activities beyond their antimicro-bial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004; 54 (1): 21–28.
  • Wolter JM, Seeney SL, McCormack JG. Macrolides in cystic fibrosis: is there a role? Am J Respir Med 2002; 1 (4): 235–241.
  • Southern KW, Barker PM. Azithromycin for cystic fibrosis. Eur Respir J 2004; 24 (5): 834–838.
  • Saiman L. The use of macrolide antibiotics in patients with cystic fibrosis. Curr Opin Pulm Med 2004; 10 (6): 515–523.
  • Pirzada OM, McGaw J, Taylor CJ, Everard ML. Improved lung function and body mass index associated with long-term use of macrolide antibiotics. J Cyst Fibrosis 2003; 2 (2): 69–71.
  • Mtairag EM, Abdelghaffar H, Douhet C, Labro MT. Role of extracellular calcium in in vitro uptake and intraphago-cytic location of macrolides. Antimicrob Agents Chemother 1995; 39: 1676–1682.
  • Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83 (9): 2451–2458.
  • Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoiet-ic cells. Cancer Res 1994; 54 (17): 4676–4679.
  • Yoshimura K, Nakamura H, Trapnell BC, et al. Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Res 1991; 19 (19): 5417–5423.
  • Graff I, Schram-Doumont A, Szpirer C. Defective pro-tein kinase C-mediated actions in cystic fibrosis neutrophils. Cell Signal 1991; 3 (3): 259–266.
  • Hudson VM. New insights into the pathogenesis of cys-tic fibrosis: pivotal role of glutathione system dysfunction and implications for therapy. Treat Respir Med 2004; 3: 353–363.
  • Dormer RL, Harris CM, Clark Z, et al. Sildenafil article (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005; 60: 55–59.
  • Kerem E. Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr Opin Pulm Med 2004; 10: 547–552.
  • Labro MT. Macrolide antibiotics: current and future uses. Exp Opin Pharmacother 2004; 5: 541–550.
  • Carr RR, Nahata MC. Azithromycin for improving pul-monary function in cystic fibrosis. Ann Pharmacother 2004; 38 (9): 1520–1524.
  • De Wachter E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J. Inhaled budesonide induced Cushing's syn-drome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibrosis 2003; 2 (2): 72–75.
  • Prunier AL, Malbruny B, Laurans M, Brouard J, Duhamel JF, Leclercq R. High rate of macrolide resistance in Staphylococcus aureus strains in patients with cystic fibrosis reveals high proportions of hypermutator strains. J Infect Dis 2003; 187: 1709–1716.
  • Maeda K, Mikasa K, Konishi M, et al. Acute exacerba-tions due to Streptococcus pneumoniae in chronic lower res-piratory infections during long-term macrolide therapy. Kansenshogaku Zasshi 2001; 75: 846–850.
  • Bauernfeind A, Jungwirth R, Eberlein E. Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. Infection 1995; 23: 316–321.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.